Drug company Teva Pharmaceuticals said Nov. 13 it will begin selling the cancer drug vincristine again after pulling it off the market earlier this year.
The medication treats cancers including Hodgkin’s disease, leukemia, non-Hodgkin’s lymphoma, and a type of brain cancer.
Pfizer was the only company left producing vincristine after the generic drug giant pulled the product from its shelves. Soon after, a shortage of the drug occurred and some cancer patients, including children, couldn’t access it.
“Teva was at times making and selling this product at a loss,” the company’s spokeswoman Kelley Dougherty told Bloomberg Law in an emailed ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.